

Natco gets approval to market chewable tablets for treating end stage renal disease

16 August 2017 | News

Natco's Lanthanum Carbonate strengths are generic equivalent of Shire Development LLC's Fosrenol chewable tablets and are indicated to reduce serum phosphate in patients with end stage renal disease (ESRD).



Natco Pharma has said that it has received approval from the US health regulator to market Lanthanum Carbonate chewable tablets used in treatment of patients with end stage renal disease.

According to a press release, Natco Pharma said in a regulatory filing that the company has received final approval from the US Food and Drug Administration (USFDA) to market Lanthanum Carbonate chewable tablets in various strengths.

"The product, as the first generic, will be launched shortly in the USA market," it added.

Natco's Lanthanum Carbonate strengths are generic equivalent of Shire Development LLC's Fosrenol chewable tablets and are indicated to reduce serum phosphate in patients with end stage renal disease (ESRD).

As per IMS MAT sales data, Fosrenol tablets had sales of USD 122.4 million during June 2017 in the US market.

Natco and Lupin had entered into an agreement on September 1, 2008 to jointly commercialise generic equivalents of Fosrenol chewable tablets.